NIP
HZNP

Nicholas Investment Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Nicholas Investment Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-103,724
Closed -$11.8M – 224
2022
Q4 		$11.8M Sell
103,724
-139,397
-57% -$11.6M 1.03% 39
2022
Q3 		$15M Buy
243,121
+28,844
+13% +$2.02M 1.39% 20
2022
Q2 		$17.1M Sell
214,277
-25,648
-11% -$2.43M 1.62% 15
2022
Q1 		$25.2M Buy
239,925
+78,862
+49% +$7.69M 1.8% 6
2021
Q4 		$17.4M Buy
161,063
+12,818
+9% +$1.4M 1.1% 20
2021
Q3 		$16.2M Sell
148,245
-79,594
-35% -$8.26M 1.19% 15
2021
Q2 		$21.3M Sell
227,839
-42,792
-16% -$3.94M 1.34% 16
2021
Q1 		$24.9M Sell
270,631
-14,415
-5% -$1.22M 1.74% 5
2020
Q4 		$20.9M Buy
285,046
+20,690
+8% +$1.54M 1.61% 15
2020
Q3 		$20.5M Buy
264,356
+212,977
+415% +$14.7M 2.22% 4
2020
Q2 		$2.86M Sell
51,379
-110,285
-68% -$4.72M 0.58% 65
2020
Q1 		$4.79M Sell
161,664
-32,775
-17% -$1.11M 0.93% 28
2019
Q4 		$7.04M Sell
194,439
-169,678
-47% -$5.2M 0.73% 30
2019
Q3 		$9.91M Buy
364,117
+152,939
+72% +$3.95M 0.83% 28
2019
Q2 		$5.08M Buy
+211,178
New +$5.36M 0.47% 74
2016
Q4 		– Sell
-243,275
Closed -$4.41M – 359
2016
Q3 		$4.41M Buy
+243,275
New +$4.75M 0.29% 122
2016
Q1 		– Sell
-483,687
Closed -$10.5M – 354
2015
Q4 		$10.5M Buy
483,687
+73,862
+18% +$1.44M 0.72% 18
2015
Q3 		$8.12M Sell
409,825
-129,076
-24% -$4.08M 0.58% 39
2015
Q2 		$18.7M Sell
538,901
-4,089
-0.8% -$125K 1.2% 4
2015
Q1 		$14.1M Sell
542,990
-88,048
-14% -$1.61M 0.88% 11
2014
Q4 		$8.13M Buy
631,038
+242,299
+62% +$3.03M 0.51% 47
2014
Q3 		$4.77M Buy
388,739
+187,200
+93% +$2.18M 0.3% 102
2014
Q2 		$3.19M Buy
201,539
+5,270
+3% +$75.2K 0.19% 185
2014
Q1 		$2.97M Buy
+196,269
New +$2.22M 0.25% 136

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nicholas Investment Partners's HZNP Position: Q1 2023 in Review

Nicholas Investment Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 103,724 shares — an estimated $11.8M sold.

Nicholas Investment Partners first reported a position in HZNP in Q1 2014 and held it in 24 quarters. The position peaked at $25.2M in Q1 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Nicholas Investment Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Nicholas Investment Partners sold 103,724 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $11.8M.
  • Nicholas Investment Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 24 quarters.
  • Nicholas Investment Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $25.2M in Q1 2022.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Nicholas Investment Partners's 13F filing for Q1 2023, filed 12 May 2023.